Restricted Mean Survival Time and Cure-Rate Modeling in Estimating Relapse-Free Survival Benefit With Adjuvant Dabrafenib + Trametinib Treatment in Melanoma

Main Article Content

John Kirkwood
Reinhard Dummer
Axel Hauschild
Mario Santinami
Victoria Atkinson
Vanna Sileni
James Larkin
Marta Nyakas
Andrew Haydon
Caroline Dutriaux
Jacob Schachter
Caroline Robert
Laurent Mortier
Hiya Banerjee
Tomas Haas
Monique Tan
Mike Lau
Dirk Schadendorf
Georgina Long
Mario Mandala

Keywords

Melanoma, BRAF inhibitor, MEK inhibitor, Adjuvant Therapy, Survival Time

Abstract

Abstract not available.

References

1. Hauschild A, et al. ASCO 2020 [abstract 10001].

2. Weber JS, et al. ESMO 2019 [abstract 1310O].

3. Eggermont AM, et al. ASCO 2020 [abstract 10000].

4. A'Hern RP. J Clin Oncol. 2016;34(28):3474-3476.

5. Kim DH, et al. JAMA Cardiol. 2017;2(11):1179-1180.

6. Pak K, et al. JAMA Oncol. 2017;3(12):1692-1696.

7. Uno H, et al. J Clin Oncol. 2014;32(22):2380-2385.

8. Othus M, et al. Clin Cancer Res. 2012;18(14):3731-3736.

9. Huang L, et al. Cancer. 2008;112(10):2289-2300.